Clinical Trials Logo

Clinical Trial Summary

CT-PET image fusion has the potential to differentiate 'tumor' from 'atelectasis' much better than the CT-scan in patients with non-small cell lung cancer who also have atelectasis.

This however has never been validated on a histological level. In this study patients with non small cell lung cancer and atelectasis who are eligible for surgery undergo a CT-scan and a PET-scan prior to surgery.

The resection specimen will be compared to the preoperative imaging.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


NCT number NCT00184964
Study type Interventional
Source Radboud University
Contact Dominic A Schinagl, MD
Phone +31243614515
Email d.schinagl@rther.umcn.nl
Status Recruiting
Phase N/A
Start date June 2004

See also
  Status Clinical Trial Phase
Completed NCT02135211 - Healthy Directions After Lung Surgery Pilot N/A
Completed NCT00191230 - Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer Phase 2
Withdrawn NCT01004419 - Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer Phase 1
Completed NCT01671332 - Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer Phase 2
Terminated NCT00905801 - Computed Tomography (CT) Perfusion Imaging of Lung Cancer N/A
Completed NCT00191256 - Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer Phase 2
Completed NCT00954278 - Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer Phase 1
Terminated NCT01282151 - TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer Phase 3
Terminated NCT01088906 - Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC Phase 2
Completed NCT00553254 - Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer Phase 2
Completed NCT01469000 - A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) Phase 2
Withdrawn NCT00934076 - Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer Phase 1
Completed NCT00798720 - Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer Phase 2
Terminated NCT01891669 - A Study Of PF-06263507 In Patients With Advanced Solid Tumors Phase 1
Completed NCT00160069 - Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer Phase 2
Completed NCT00548093 - PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib Phase 2